Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rostafuroxin · 1 trial · 1 indication
Automated sitting and standing SBP and DBP will be recorded by physician at baseline (two visits) and at week 2, 5 and 9 of treatement. sitting: after the patient has rested for at least 10 minutes in a quiet room. There are five consecutive sitting BP readings with a 30 to 60 seconds interval between the readings; the mean of the last three sitting BP will be used.
| Arm | Type | Description |
|---|---|---|
| Rostafuroxin 6 micrograms capsules | EXPERIMENTAL | 1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast. |
| Rostafuroxin 50 micrograms capsules | EXPERIMENTAL | 1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast. |
| Rostafuroxin 500 micrograms | EXPERIMENTAL | 1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast. |
| Losartan 50 mg encapsulated | ACTIVE_COMPARATOR | 1 capsule containing one cpr of Losartan 50 mg once a day before breakfast. |
| Name | Type | Description |
|---|---|---|
| Rostafuroxin | DRUG | This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model. |
| Losartan | DRUG | COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt. |
Inclusion Criteria: * Signature of a written informed consent, included informed consent on genotype analysis. * Naive hypertensive patient (new diagnosed patient, never treated before). * Documented mild to moderate arterial hypertension: SBP comprised between 140 and 169 mmHg and DBP between 85 a...
Rostafuroxin is an investigational small molecule being developed for the treatment of hypertension. It is currently in Phase 2 clinical development and has been studied in a completed trial in Taiwan. The drug is not yet approved and remains under investigation for its antihypertensive effects.
Rostafuroxin is being developed by Windtree Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol WINT. The company is conducting clinical research on this small molecule for the treatment of hypertension.
Rostafuroxin is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not yet approved by regulatory authorities. The drug remains investigational and is being studied for its potential use in treating hypertension.
Rostafuroxin has been studied in one completed Phase 2 clinical trial with the identifier NCT03217825. This trial, titled "Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan," enrolled 240 participants with hypertension in Taiwan. The study was randomized, double-blind, and active-controlled.
No, Rostafuroxin is not the same as Losartan. Rostafuroxin is an investigational small molecule being developed by Windtree Therapeutics for hypertension, while Losartan is an approved angiotensin II receptor blocker used as an active comparator in the clinical trial. The trial compared different doses of Rostafuroxin against Losartan.